“Mac,” as just about everyone in Portland knows him, is a pharmacist and pharmacy teacher deeply concerned about a dangerous new practice in which several companies appear to be selling non-FDA approved and potentially adulterated medicines to Maine patients.
Most Recent Posts
Collaboration was rightly a focal point of #PhRMA14 because it is incredibly important to developing new medicines. As PhRMA CEO John Castellani said at the meeting, the industry is changing rapidly and we continue to compete by “joining hands…building new strength and breadth…[and] adapting and leading.” One of the most important ways to accomplish this is by incorporating the patient into everything we do.
The final day of #PhRMA14 concluded with Celgene CEO Bob Hugin passing the Chairman’s gavel to Pfizer CEO Ian Read. It has been a successful three days and our current momentum will undoubtedly propel us into another year of research and innovation. Governor Terry McAuliffe said it best this morning by noting that innovative solutions often happen through collaboration.
As the twelve countries negotiating the Trans-Pacific Partnership (TPP) approach the finish line after years of hard work on an ambitious agreement, there remains quite a bit of work left to be done. Now that all the low hanging fruit has been picked, the most difficult issues remain to be finalized., Much of the criticism of TPP from outside groups is based on flawed or false assumptions that severely understate the role of intellectual property in developing new and lifesaving medicines.
Day two of #PhRMA14 was chock full of insightful conversations focused on the current state of the biopharmaceutical industry and what it will take to continue to innovate.
The following is a guest blog post from Information Technology and Innovation Foundation President Rob Atkinson, who participated on a panel today at #PhRMA14 that discussed the value of medical innovation.
The guest post below by Robert Hugin originally appeard on The Hill. Hugin is the chairman and CEO of Celgene Corporation and chairman of PhRMA.
America's status as the research lab for the world is no longer secure.
Day one of #PhRMA14 was a success! Celgene CEO and PhRMA Chairman Bob Hugin set the tone for the meeting by emphasizing the industry’s commitment to the patient. It is because of that commitment that we have seen tremendous progress and a real prospect of producing dramatic breakthroughs. Yet, there are still challenges that must be addressed, and discussions tomorrow will speak to six key initiatives to help address them.
After many months of planning and hard work, I’m excited for the kick-off of PhRMA’s 2014 Annual Meeting tomorrow afternoon at 4pm. I think we have a great meeting planned – and I’m thrilled to announce that nearly all of it will be live-streamed on our website.
This month, the Institute of Medicine released a summary of a workshop I participated in that addressed the critical role of collaboration within the biopharmaceutical industry. As part of this program, academia, providers, industry professionals, patient advocates and government regulators shared their perspectives.
Another year of innovative research and development (R&D) to help patients around the world live longer, healthier lives has flown by. Beginning April 9, leaders from the biopharmaceutical industry, patient advocates, regulators, academics and others will gather in Washington, D.C. for this year’s PhRMA Annual Meeting.
This month, a New York Times editorial discussed the cost of a new drug to treat hepatitis C. The opinion piece took a short-term view of treating the disease, noting that a panel of experts concluded that the drug offered “low value” for treating most patients, in large part due to its cost.
Helen Keller once said, “Alone we can do so little; together we can do so much.”While all members of the biopharmaceutical industry are working toward the common goal of improving patient health, it is through collaboration that we have seen diseases eradicated and innovative treatments emerge from the pipeline. This week, we highlight some of the collaborative efforts currently underway to help patients across the world.
This week’s Medicines in Development report for Parkinson’s disease examines the work currently underway to help the 1.5 million Americans who are affected by the progressive neurological condition. While high-profile Parkinson’s patients like Michael J.